Adverum is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related macular degeneration (wAMD). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, Adverum generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Adverum’s core capabilities include clinical development and in-house manufacturing expertise, specifically in process development and assay development.
Adverum Biotechnologies NASDAQ:
01/23/18 10:56 PM EST
Data provided by Nasdaq.
Minimum 15 minutes delayed.
- Jan 4 2018
Summary ToggleAdverum Biotechnologies Provides 2018 Outlook
- Dec 28 2017
Summary ToggleAdverum Biotechnologies Doses First Patient in the ADVANCE Phase 1/2 Clinical Trial of ADVM-043 for A1AT Deficiency
- Dec 5 2017
Summary ToggleAdverum Biotechnologies Begins Patient Enrollment in the ADVANCE Phase 1/2 Clinical Trial for A1AT Deficiency
- Nov 15 2017
Summary ToggleAdverum Biotechnologies to Present at Upcoming Conferences
There are currently no events to display.